Pramlintide, an amylin analogue, slows gastric emptying, suppresses glucagon, and promotes satiety.

• A. Slowing gastric emptying, suppressing glucagon, promoting satiety
• B. Increases insulin resistance
• C. Increases hepatic glucose production
• D. Enhances SGLT2 activity

Answer: (A)

Pramlintide, as an amylin analogue, slows gastric emptying, suppresses glucagon, and promotes satiety. These actions work together to blunt postprandial glucose rises: delaying how quickly food leaves the stomach slows the influx of glucose, reducing the spike after meals; lowering glucagon decreases hepatic glucose production during the post-meal period; and increasing satiety helps reduce overall caloric intake, supporting better weight and glucose control. The other options don’t fit this drug’s profile—pramlintide does not increase insulin resistance, it does not raise hepatic glucose production, and it is not related to enhancing SGLT2 activity.